Overview
Neuromyelitis optica spectrum disorder (NMOSD) is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis).

Enspryng is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.

Coverage Guidelines
Authorization may be reviewed for members new to AllWays Health Partners who are currently receiving treatment with Enspryng, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs

OR
Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:
1. The member has a diagnosis of neuromyelitis optica spectrum disorder
2. The member has a diagnosis is anti-aquaporin-4 (AQP4) antibody positive
3. The member exhibits at least one of the following core characteristics of NMOSD
   a. Optic Neuritis
   b. Acute myelitis
   c. Area postrema syndrome (episode of otherwise unexplained hiccups or nausea and vomiting)
   d. Acute brainstem syndrome
   e. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions
4. The member will not receive the requested drug concomitantly with other biologics for the treatment of NMOSD
5. The member is ≥18 years of age

**Continuation of Therapy**
Reauthorizations may be granted when patient demonstrates a positive response to therapy and the member will not receive Enspryng in combination with other biologics for the treatment of NMOSD.

**Limitations**
1. Initial approvals and reauthorizations will be for 12 months.
2. The following quantity limits apply:

| Enspryng 120mg/mL (1mL) | 1mL per 28 days |

**References**

**Review History**
3/17/2021 – Created and Reviewed at March P&T. Effective 05/01/2021

**Disclaimer**
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.